RxDoctor Payments Data

Mark Haberman, MD

Internal Medicine · Escondido, CANPI 1497780563

Payments from drug & device makers

$611in general payments, 2019–2025

Across 28 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$149
  • Biotronik Inc.$146
  • Lilly USA, LLC$78
  • AbbVie$47
  • Kowa Pharmaceuticals America, Inc.$30
  • Dexcom, Inc.$29
  • plus $132 from 8 others

What the payments were for

  • Food & beverage$59397%
  • Other$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$611 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$88,859
Medicare patients
193
Services billed
958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$121,682
OzempicSemaglutide69$87,984
JanuviaSitagliptin Phosphate62$76,825
JardianceEmpagliflozin49$66,409
TrulicityDulaglutide25$40,327
XareltoRivaroxaban17$17,066
RybelsusSemaglutide18$16,851
MounjaroTirzepatide13$13,649
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$10,366
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$10,112
Incruse ElliptaUmeclidinium Bromide16$8,673
MyrbetriqMirabegron14$6,449
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$5,625
Breo ElliptaFluticasone/Vilanterol12$4,804
Tiotropium Bromide12$4,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$11$104,83487 claims
Lilly USA, LLCTrulicity, Mounjaro$78$53,97538 claims
GSKAnoro Ellipta, Incruse Ellipta, Breo Ellipta$149$23,58949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Escondido

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →